#Oncology

🏢Release 📈 Stocks — 📊 Neutral

Pyramid Pharma Services Launches New Cartridge Program for Blood Cancer Drugs

November 3, 2026 (1 hour ago)

Pyramid Pharma Services expands its CDMO capabilities with a new cartridge-based manufacturing platform designed to accelerate the delivery of life-saving rare blood…

🌍 US Read More →

🏢Release 📈 Stocks — 📊 Neutral

Privo Technologies Secures New Patents for Advanced Drug Delivery Platforms

November 2, 2026 (22 hours ago)

Privo Technologies strengthens its clinical-stage biopharmaceutical position by securing new patents for its proprietary drug delivery platforms, enhancing its competitive edge in…

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Endeavor Health and GoPath Diagnostics Launch Novel Prostate Cancer Test

November 2, 2026 (22 hours ago)

Endeavor Health and GoPath Diagnostics introduce a new genetic screening tool for aggressive prostate cancer, aiming to improve clinical outcomes through early…

Endeavor Health GoPath Diagnostics

🌍 AMERICAS Read More →

🏢Release 📈 Stocks — 📊 Neutral

FCS Physicians Highlight NCODA 2026 Summit Focus on Patient-Centered Care

October 30, 2026 (3 days ago)

Florida Cancer Specialists & Research Institute leaders wrap up the NCODA 2026 International Fall Summit, emphasizing advancements in oncology education and patient-centric…

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Jiangsu Hengrui Medicine Presents 64 Oncology Research Abstracts at ESMO 2026

October 29, 2026 (5 days ago)

Jiangsu Hengrui Pharmaceuticals highlights its global oncology R&D capabilities with 64 research abstracts presented at the 2026 ESMO congress in Madrid.

600276.SS

🌍 ASIA Read More →

🏢Release 📈 Stocks

HERVolution Validates IPT-001 Pipeline With HERV-K Expression Data

October 28, 2026 (5 days ago)

HERVolution shares gain momentum as new clinical data confirms HERV-K expression in 43 cancer types, validating the therapeutic potential of the company's…

HERVolution

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Genmab Shares Rally as Petosemtamab Trial Cuts Death Risk by 50%

October 28, 2026 (6 days ago)

Genmab's petosemtamab combination therapy significantly improved survival rates in a Phase 3 head and neck cancer trial, meeting dual primary endpoints and…

GMAB

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Genmab Reports 28.2 Months Median Survival in Phase 2 Head and Neck Cancer Trial

October 26, 2026 (8 days ago)

Genmab's petosemtamab combination therapy shows strong efficacy in Phase 2 trials for head and neck cancer, achieving a 28.2-month median overall survival…

GMAB

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Innovent Biologics Gains NMPA Nod for Sintilimab in Advanced Melanoma

October 26, 2026 (8 days ago)

Innovent Biologics advances its oncology pipeline as the NMPA accepts a new indication application for sintilimab to treat advanced melanoma, signaling potential…

01801.HK

🌍 ASIA Read More →

🏢Release 📈 Stocks

Genmab and Incyte Partner to Test New Colorectal Cancer Treatment Combo

October 25, 2026 (8 days ago)

Biotech firms Genmab and Incyte are joining forces to test a new combination therapy targeting KRAS G12D-mutated colorectal cancer, a common and…

GMAB INCY

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Genmab Reports Strong Phase 2 Data for Petosemtamab in Colorectal Cancer

October 25, 2026 (9 days ago)

Genmab's petosemtamab shows durable clinical activity in metastatic colorectal cancer, with 81% response rates in specific patient subgroups, bolstering the firm's Phase…

GMAB

🌍 EUROPE Read More →

🏢Release 📈 Stocks

Eli Lilly Reports Positive Phase Data for Olomorasib in NSCLC Treatment

October 25, 2026 (9 days ago)

Eli Lilly's olomorasib shows clinical promise in first-line NSCLC treatment, potentially bolstering the company's oncology pipeline following positive ESMO data.

LLY

🌍 AMERICAS Read More →